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The usage of psychotropic (Table 1)
medication is considerable world
wide. In Malta, this can be attested
to by the numerous studies that
have been conducted by the
University of Malta Department of
Pharmacy (in conjuction with other
institutions and individuals).
This could be an indictment to the
prescribing trends of psychotropic
medication, and, also, to the structures
in place with the objective of
controlling the usage but which may
also be proving to be the barriers to
the timely intervention of pharmacists
to influence the rational use of these
medicines and to deliver effective
pharmaceutical care services.
On the other hand, and most
significantly, the traditional informality
and accessibility of our community
pharmacies do not carry the “stigma” of
“psychiatric services”, although
understandably, some patients do find
it difficult to discuss their condition
where there is lack of privacy.
Community pharmacists are in a
unique position to support community-
based patients through advice,
counselling and monitoring of their
medication regimes; together with
providing support, and acting as an
information resource, to carers and
family members, where relevant.
Pharmacists can also act as “gate-
keepers” to the national health
services, by referring to the family
doctor or caring consultant
psychiatrist, those patients who are
defaulting or are not able to maintain
their medication regime. This
necessitates an in-depth knowledge of
psychotropic medicines and their use,
so that pharmacists are able to
effectively influence the management
of psychiatric medication and attain
therapeutic objectives  with outcomes
that guarantee the improvement of
patients’ quality of life.
Pharmacists should also be familiar
with the main psychiatric disorders.
In parenthesis, however, one must
not overlook the fact that pharmacists’
knowledge on medicines may be a
determinant factor in “differentially
diagnosing” drug-induced mental
health disorders and suitably advising,
counseling and referring patients for
review of their medication.
Psychiatric Disorders:
Classification And Range
Psychiatric disorders are classified
to identify groups of patients who share
similar clinical features so that suitable
treatment can be planned and the likely
outcome predicted. Diagnosis is
“syndrome” based, depending on the
symptoms and the phenomena
observed; this is due to the fact that
aetiology and underlying physical and
psychological pathology are still only
partially understood.
Two major classifications for
Psychiatric Disorders are in use:
• The WHO, ICD-10  - International
Classification of Diseases 10th
Edition, in use in Malta since 1994;
• The DSM-IV -  Diagnostic And
Statistical Manual (IV) Of Mental
Disorders, Fourth Edition,
Washington DC, Criteria American
Psychiatric Association 1994
A basic classification of mental
illnesses, which would suffice within
the context of this review (and is not
according to the rigid parameters of
either the ICD or DSM), subdivides them
into two major groups, psychoses and
neuroses.
Psychoses are major mental illness
which are characterized by severe
symptoms, such as disturbance of
thinking, e.g., delusions; and of
emotions etc., e.g., hallucinations.
They are themselves subdivided into
organic psychoses, e.g. dementia, and
functional psychoses, e.g.,
schizophrenia and the affective
disorders such as depression and mania
. Neuroses have symptoms which are
much closer to normal experience.
Other disorders include those
associated with substance addiction.
Completion of Assessment Questions following this article
entitles members to one credit towards C.E. requirement.
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Table 1 Psychoactive/Psychotropic
• The term psychoactive embraces all those substances
which affect the mind, including narcotics and
psychotropic drugs.
 • “Psychotropic” covers only those which influence
mental processes and can lead to dependence.
Source: World Health Organisation. Report Of The Working Group On The Role
Of Schools Of Pharmacy In The Rational Use Of Psychoactive Drugs. London,
1989
Table 2 Classification Of Psychotropic Drugs By
Chemical And Pharmacological Sub-Groups
•  tranquillizers-anxiolytics,
•  anxiolytics-antipsychotics
•  neuroleptics and antipsychotics
•  sympathomimetics
•  nootropics
•  MAOI
•  antidepressants
•  antiparkinsonian drugs
•  anticonvulsants
•  hallucinogenic agents
•  additional groups
Source:Psychotropics 1997/98
Table 3 Classification Of Psychotropics Viewed As
Drugs Acting On The Central Nervous System
•  Hypnotics
•  Anxiolytics
•  Barbiturates
Drugs Used In Psychoses & Related Disorders
•  Antipsychotics
•  Antipsychotic Depot
•  Antimanic Drugs
Antidepressant Drugs
•  Tricyclic And Related Antidepressant Drugs
•  MAOI
•  SSRIs And Related Drugs
•  Other Antidepressant Drugs
Source: BNF, September 1997
Table 4 Rational Use
Rational use means that the right drug will be
taken by the right patient, in the right dose,
and for the right duration of therapy, and that
the risks of therapy will be acceptable.
Source:  World Health Organisation. Report Of The Working Group
On The Role Of Schools Of Pharmacy In The Rational Use Of
Psychoactive Drugs. London, 1989.
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Psychotropic Drugs:
An Overview
It is not within the context of this
article to address the individual drug
classes,(Tables 2 and 3) but reference
will be made to the main drugs in use,
particularly, in practice settings, and
with regard to, for example, clinically
significant drug interactions and side
effects, together with other factors
which may limit their rational use
(Table 4).
Classical (Typical) And
Atypical Antispychotics
Historically, the use of the classical
typical antipsychotics such as the
thioxanthenes, e.g., flupenthixol and
clopenthixol, the phenothiazines e.g.
fluphenazine, and butyrephenones, e.g.,
haloperidol, in their various forms, has
caused concern about their use
including the occurrence of side effects
such as extrapyramidal symptoms (EPS),
tardive dyskinesia, sudden death,
neuroleptic malignant syndrome and
hormonal disturbance. Other issues,
such as non-compliance which may be
due to a lack of patients’ and carers’
understanding of  the condition and the
importance of medication to treatment
and prevention of relapse, together
with antipsychotic polypharmacy,
excessive use of anticholinergic drugs,
excessive doses of the antipsychotics
themselves have also raised concerns.
Doses of atypical antipsychotics
e.g., clozapine, have also been reported
to be too high. These drugs have been
introduced into clinical use relatively
recently and have less EPS and
prolactin-related effects, but, they do
not do not belong to a specific class
(hence, atypical).
Clozapine has been reported to be
the only atypical antipsychotic with
proven efficacy in refractory
schizophrenia; while it lacks EPS, it has
been associated with a range of other
adverse effects including
agranulocytosis, necessitating regular
blood monitoring in patients requiring
this treatment.
Mood Stablilisers
Many mood stablisers are the result
of serendipitous discovery. Those in
current use include lithium,
carbamezapine, sodium valproate and
other anticonvulsants, thyroid
hormones and calcium channel
blockers.
The most common failure of therapy
is non-compliance. Mood disorders
could be resistant to single agents,
polypharmcy is therefore common and
pharmacists’ focus should be on side
effects and interactions.
Lithium with its long half life and
narrow therapeutic index requires serum
level monitoring. Monitoring is a clear
indication of the degree of compliance
by patients to the medication and is a
valuable tool to educate the patients
and inform them on the outcome
options basing on their understanding
of the importance of their adherence to
their treatment plan. Serum levels are
also a quality assurance tool of the
prescribing practices of lithium, to
ensure that patients are not receiving
too high or too low a dose, but the
right dose for the management of a
particular patient.
The pharmacist should focus on the
propensity for interaction of lithium
with other drugs.  The likelihood of the
occurrence of clinically significant
interactions is increased with drugs
that
• induce or inhibit hepatic microsomal
enzymes
• have a low therapeutic index
• have a muliplicity of pharmacologic
action
• and in high risk patient groups,
such as the elderly, mentally ill and
substance abusers.
The most common interactions, with
a potential tolead to intoxication, are
those with Non-Steroidal Anti-
inflammatory Drugs, with reported
increases in serum lithium levels of up
to 60%; and with different diuretics
and antihypertensive agents.  The
concomitant administration of lithium
with other psychotropics, such as
carbamezapine and other TCAs is
relatively safe with strict monitoring of
serum lithium levels.
 It is suitable to remember that the
ingestion of sodium chloride and
sodium bicarbonate can cause a
decrease in serum lithium levels.
The side-effect profile of lithium
must also be given attention. These
range from the transient, such as
nausea, to the persistent but harmless
(and which appear with normal serum
lithium levels), such as weight gain, to
the ones that are prodromal to
intoxication.  Pharmacists can help
patients  to be alert to recognise these
symptoms.
Antidepressants
Optimal outcomes can be achieved
if commencement of treatment with
antidepressants is not delayed, is
vigorous and continued for at least 4- 6
months after the initial response.
Achievement of these objectives
however appear to be limited in
practice. resulting in poor patient
outcomes in the management of
depression.
Pharmacoepidemiological studies
suggest that patients who are treated
with the older tricyclic antidepressants
(TCAs) rarely completed an effective
course of treatment, either in terms of
receiving an adequate dose of
antidepressant or completing a
minimum period of treatment when an
adequate dose was achieved. Initial
choice of antidepressant appeared to be
an important factor in determining
subsequent treatment patterns;
patients who began treatment with a
selective serotonin reuptake inhibitor
(SSRI) were considerably more likely to
complete an effective course of
treatment which should be reflected in
better outcomes including better
quality of life outcomes.
The pharmacist must also be aware
of the varied indications associated
with the use of the TCAs ,which may
preclude their prescription for
“psychiatric” needs, but, for example,
may be used for the treatment of pain.
In giving advice, the pharmacist must
identify the prescriber’s objective and
not volunteer information that might
undermine the patient’s trust in the
prescriber and in the treatment .
Consideration of the
pharmacokinetic profile of SSRIs may
prove useful to support the choice of
medication in specific cases. This is
often overlooked and can lead to
inadequate treatment and outcome.
Prevention Of Relapse
It is well established that
antidepressants, antipsychotics and
mood stablisers prevent relapse if taken
long-term. This however places a great
deal of responsibility on the patients
themselves, who will only comply if
they accepted that something was
wrong, that it needed correcting, that
medication would help and that the
risk-benefit ratio was acceptable.
Common reasons for discontinuation
of psychotropics by patients include
side effects (even if manageable), fear
of addiction, lack of knowledge that the
treatment prevented relapse, and
pressure from (usually uninformed)
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relatives and friends.
A positive attitude towards their
treatment was generally essential for
attaining objectives of better
outcomes, particularly in the long term.
A number of studies have shown the
advantages of structured education and
support  of patients, and the
subsequent positive effect on attitude
and hence, adherence to treatment
plans, prevention of relapse and quality
of life.
Hypnotics and Anxiolytics
Benzodiazepines (Table 5) are the
most commonly used anxiolytics and
hypnotics. Studies have shown that in
1989, 11.92% of the Maltese
population had consumed
benzodiazepines; and since 1993, there
has been a change in the prescribing
trend towards the shorter acting
benzodiazepines such as lorazepam and
triazolam, especially in the elderly
(<66yrs).
However, in 1995, there were still a
high 48.4% of elderly patients receiving
long acting benzodiazepines such as,
diazepam, Subsequently, it was
confirmed that, in 1997, there was a
consistent increase in benzodiazepine
prescribing in the 45-65 age group.
Females are also consistently reported
to be the largest group of patients
consuming benzodiazepines, accounting
for more than double their male
counterparts.
The needs of all patients to whom
benzodiazepines have been prescribed
should be addressed by pharmacists
who should refrain from acting as
“passive conduits” complying to the
legal requirements alone in the
dispensing of benzodiazepines. Some of
these needs are of a general nature
whilst others are specific to the age
group and, in some cases, to the gender
concerned e.g. pregnancy and lactation.
It is to be emphasized that
benzodiazepines have a “broad
spectrum” of indications  and may also
be prescribed  for their action as e.g.,
muscle relaxant, anticonvulsant and
antiepileptic properties.
Dosage and dosage regimens require
particular attention not only from the
legal supply aspect but with
consideration to the management of
the condition, prevention of misuse and
the possible diversion of
benzodiazepines to illicit use.
In consideration of adverse effects
of benzodiazepines, the potential for
the development of tolerance,
dependence (Table 6) and the
withdrawal syndrome must be given due
regard. For example, patients should be
warned of the effect of abrupt
discontinuation of the medication
which can result in increased anxiety,
sleep disorder, aching limbs,
nervousness, nausea, and influenza-like
symptoms; and referred to their caring
physician should they feel ready to
discontinue their therapy.
Particularly in the elderly, problems
associated with ataxia and consequent
falls and injury, confusion, memory loss
and cognitive impairment require
attention.
The additive effects of
benzodiazepines when administered in
combination with alcohol and other
CNS depressants such as neuroleptics
and antipsychotics, hypnotics,
anxiolytics and sedatives,
antidepressants, narcotic analgesics -
which can also lead to euphoria,
enhancing the potential for psychic
dependence of the latter - antiepileptic
drugs and anaesthetics should also be
of concern. Other potentially clinically
significant drug interactions include the
temporary increase of the sedative
effect of benzodiazepines by the
concomitant administration of
cispiride; the possible enhancement of
the activity of benzodiazepines by
those drugs which inhibit certain
hepatic enzymes particularly
cytochrome P 450.
Zolpidem and chlormethiazole have
a place as hypnotics for short term use,
Table 5 Committee On Safety Of Medicines (UK) Advice
1. Benzodiazepines are indicated for the short-term (two to four weeks only)
relief of anxiety that is severe, disabling or subjecting the individual to
unacceptable distress, occurring alone or in association with insomnia or
short-term psychosomatic, organic or psychotic illness.
2. The use of benzodiazepines to treat short-term, ‘mild’ anxiety is
inappropriate and unsuitable.
3. Benzodiazepines should be used to treat insomnia only when it is severe,
disabling or when it is subjecting the individual to extreme distress.
Source: British National Formulary, Number 34 (September 1997)
Table 6 Definition - (Substance) Dependence
A maladaptive pattern of substance use, leading to clinically
significant impairment or distress as manifested by three or more of
the following ocurring at any time in a time period:
1) tolerance, as defined by either of the following:
a) need for markedly increased amounts to achieve (intoxication or) the
desired effects
b) markedly diminished effect with continual use of the same amount,
2) withdrawal, as manifested by either of the following:
a) the characteristic withdrawal syndrome for the substance
b) the same (or a closely related) substance is taken to relieve or avoid
withdrawal symptoms.
3) the substance is often taken in larger amounts or over a longer period than
was intended
4) there is a persistent desire or unsuccessful efforts to cut down or control
substance abuse
5) a great deal of time is spent in activities necessary to obtain the substance
e.g. visiting multiple doctors or driving long distances, use the substance
(e.g. chain-smoking) or recover from its effects.
6) important social occupational, or recreational activities are given up or
reduced because of substance abuse;
7) the substance use is continued despite knowledge of having a persistent or
recurrent physical or psychological problem is caused or exacerbated by the
substance.(e.g. continuing to drink alcohol despite ulcer in stomach)
Source: Adapted from Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Washington DC, Criteria American Psychiatric Association 1994
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the latter particularly in the elderly.
Their relative freedom from a ‘hang-
over’ effect makes them particularly
useful drugs. Chlomethiazole has a
place in the treatment of alcohol
withdrawal in the younger patients.
Pharmacists should be vigilant for the
phenomenon of abuse that has recently
been associated with the use of these
drugs.
Psychotropic Medication and
Driving Performance
Benzodiazepines together with
other psychotropic drugs such as
sedating tricyclic antidepressants, many
anticonvulsants, neuroleptics may
adversely effect driving performance
and also the operating of machinery.
Patients should be warned that
drowsiness and impairment of
psychomotor function as produced by
sedating TCAs  can impair driving
performance.
This can occur with some drugs only
on the first few days of treatment, but
subsequently, there can be a slowing of
reaction time and loss of mental
concentration Moreover, psychotropic
drugs can alter the patients’ perception
of their driving skills and the dangers
on the road.
Drug induced side effects unrelated
to drowsiness can also impair patients
ability to drive. These include
anticholinergic side effects also
associated with the TCAs ,such as
blurred vision, dizziness and nausea.
Patients should be advised for example,
not to drive if unwell, to stop
immediately, and take small breaks.
Long acting hypnotics and
anxiolytics are associated with daytime
sedation and drowsiness, together with
impaired performance of complex hand-
eye coordination tasks, increased
reaction time and impaired cognitive
function.
Attention should also be given to
the potential interaction of dispensed
pharmacist recommended medicines
with these prescription drugs.
Needless to say, the combination of
alcohol with these medicines
exacerbates these effects, especially in
the elderly.
Pharmacists should clearly warn
patients, both verbally and in writing,
of these serious potential effects on
traffic safety. A written note will act as
a reminder when they are home.
Conclusion
Pharmacists are in an ideal position
to respond to special needs of
psychiatric patients (Table 7) .They
can:
• identify undiagnosed conditions, eg,
depression, and refer to family
doctor;
• reassure patients and carers  and
encourage them to seek treatment;
• support vulnerable patients  and
involve carers and/or family, whilst
ensuring confidentiality;
• educate patients about their
condition and its management and
in particular, about their
medication;
• encourage compliance and
concordance, without ignoring
patient vulnerability;
• monitor patient progress and avoid
or minise adverse drug effects to
achieve therapeutic objectives and
improve patients’ quality of life;.
• liase with other health professionals
for better patient care and
outcomes.
Table 7 Case Study - An Example of Pharmaceutical Care
Considerations Of Patients Undergoing Treatment
With Psychotropic Medication
Mrs. Borg is a 55 year-old woman who presents her pharmacist with a
prescription for a maintenance dose of a combination product containing
fluphenazine hydrochloride 500 mcgs and nortriptyline 10 mgs. Mrs. Borg
says that she is undecided whether to continue with her treatment since
she has noted that she has been putting on weight and this is further
increasing her distress.
• The pharmacist notes that Mrs. Borg is not a new patient, but on referring
to the daily register, he notes that a number of months have elapsed since
she has come to the pharmacy to refill her prescription.
• The pharmacist is concerned that if Mrs. Borg defaults on her therapy she
could suffer a relapse. This would be a great pity as Mrs. Borg has been
successfully controlled and maintained in the community where she has
been improving her quality of life.
• The pharmacist takes the advantage of not having any patients or other
clients in the pharmacy at the time and asks Mrs. Borg to sit down in a
quiet corner and tell him more about her concerns.
• As she sits down, Mrs. Borg says that since her only son’s wedding 3
months ago, she has found that she has plenty of time to herself and has
taken to sit for long hours watching television and eating her favourite
chocolates. She has also found that she has more time to sit at table with
her husband during meals and has been adding little gourmet pleasures to
their normal menu.
• The pharmacist explains that whilst the medicine itself may be responsible
for some weight gain, the changed eating habits may have been more
decisive in her case. Since the depression had been well controlled and she
was feeling better, the pharmacist reinforced his counselling to empower
Mrs. Borg to understand her condition and to achieve concordance with the
medication regimen, with advice on healthy eating habits and other
lifestyle modifications, including, exercise such as walking and the taking
up of a hobby. He also gave her a leaflet in Maltese called “Kul ghall-
sahtek” together with another one on depression.
• Mrs. Borg agreed to take the medicine for a month, after which she would
return to the pharmacy to weigh herself. The pharmacist then invited her
to check her weight and recorded it. He suggested that should there be no
decrease in her weight after one month, then he would refer her to her
family doctor for review of her medication.
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Through a concerted
endeavour the barriers
preventing pharmacists’ full
interventions in this
important area of care can
be identified and overcome.
This is most significant at
this moment in time when
the health system is moving
towards a policy of
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decreasing
institutionalisation of
psychiatric patients and
enhancing community based
services, Pharmacists are the
natural but still underutilised
resource for this highly
vulnerable patient group,
their families and carers and
the health system.  ✱
“Pharmaceutical care requires co-operation,
communication and consistency among pharmacists as
well as between pharmacists and other professionals.”
Hepler
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1. Community Pharmacies can
offer professional care services
to psychiatric patients because
pharmacies are:
a. not identified with”
psychiatric services”
b. can offer privacy facilities
c. assure confidentiality
d. all of the above
2. Pharmacists can support
community based psychiatric
patients by:
a. offering advice and
counseling on their treatment
b. monitoring progress and
outcomes
c. providing support to patients
and carers
d. all of the above
3. To influence the rational use of
psychotropic medicines
pharmacists must
a. be familiar with the main
psychiatric disorders
b. be familiar with drug
induced mental health disorders
c. have insight into the needs
of psychiatric patients
d. all of the above
4 A side effect which is specific
to the use of clozapine is
a. tardive dyskinesia
b  neuroleptic malignant
syndrome
c  agranulocytosis
d prolactin-related
The Pharmacist’s Response to the Needs of Patients
Undergoing Treatment With Psychotropic Medication
Assessment Questions:
Booklets have been produced by
the Department of Pharmacy,
University of Malta as part of
BPharm(Hons) projects.
These include:
• It-terapija tal-Lithium -  X’ghandu
jkun jaf il-pazjent. There is also
an accompanying video on this
subject in English and Maltese
• The Pharmacist and Safe Driving -
The Influence Of Medicines,
Alcohol And Drugs on Driving
Other printed material includes:
• Is-sahha mentali - Department of
Health Promotion
Sedqa leaflets
• Stop Droga campaign booklets
and leaflets, Malta Chamber of
Pharmacists
Pharmaceutical Companies with an
interest in Psychiatry also
produce patient-oriented  leaflets
on mental disorders, their
treatment and management.
5. The likelihood of occurrence of
clinically significant
interactions of lithium is
increased
a. with drugs that have a low
therapeutic index
b. with drugs that have a
multiplicity of pharmacological
action
c. in high risk patient groups
d.  in all of the above
situations
6. The concomitant administration
of lithium with one of the
following drugs is relatively
safe with strict serum lithium
levels monitoring
a. NSAIDs
b. anthypertensives
c. diuretics
d. carbamezapine
7. Optimal outcomes in depression
can be achieved if treatment is
a. is discontinued on achieving
response
b. is delayed
c. is continued for at least 4-6
months after initial response
d. none of the above.
8. Patients who are treated with
the older TCAs
a. rarely complete an effective
course of treatment
b. may not receive an adequate
dose of antidepressant
c. may not complete a
minimum period of treatment
when an adequate dose was
achieved
d. may not be suffering from
psychiatric illness
e. all of the above
9. Patients who are treated with an
SSRI
a. have poorer outcomes than
with TCAs
b. are more likely to complete
an effective course of
treatmeny
c. do not have better quality of
life outcomes than with older
TCAs.
d.  all of the above
10. Antidepressants, mood
stabilisers and antipsychotics
prevent relapse if taken long-
term, depending on whether
a. patients accept that
something is wrong with them
b. patients accept that what is
wrong with them needs
correcting
c. patients accept that
medication would help
d. all of the above
11. Common reasons for the
discontinuation of psychotropic
medicines by patients include
a. side effects (even if
manageable)
b. fear of addiction
c. lack of knowledge that
treatment prevented relapse
d. all of the above
12. Prolonged treatment with
benzodiazepines can result in
a.influenza-like symptoms
b.withdrawal syndrome
c. .tolerance and dependence
d. all of the above
13. The abrupt discontinuation of
benzodiazepine treatment can
result in
a. anxiety
b. influenza-like symptoms
c. sleep disorder
d. all of the above
14. Which of the following should
be registered in the Register of
Psychotropic drugs
a. citalopram
b. zolpidem
c. chlormethiazole
d. all of the above
15. Elderly patients on
benzodiazepine treatment must
receive the pharmacist’s special
attention with regard to
a. possibility of falls and injury
b. confusion
c. memory loss and cognative
impairment
d. all of the above
16. Additive effects of concern are
a result of the co-
administration of
benzodiazepines with the
following drugs
a. alcohol
b. narcotic analgesics
c. anaesthetics
d. all of the above
17. The following psychotropic
medicines can have serious
effects on driving performance
a. benzodiazepines
b. neuroleptics
c. sedating TCAs
d. all of the above
18 Pharmacists should warn
patients on the adverse effects
of psychotropic medication on
driving performance including
a. daytime sedation and
drowsiness produced by long-
acting hypnotics and
anxiolytics
b .daytime induced
anticholinergic side effects of
TCAs such asblurred vision,
dizziness and nausea
c. impaired performance of
complex hand-eye coordination
tasks, increased reaction time
and impaired cognitive
function produced by
benzodiazepines
d. all of the above
19. Pharmacists can respond to the
needs of psychiatric patients by
a. identifying undiagnosed
conditions and referring to the
family doctor
b. supporting them  and
involving carers/family, whilst
ensuring confidentiality
c. monitoring their progress
and intervening where
necessary in liaison with other
carers to achieve therapeutic
and quality of  life outcomes
d. all of the above
20, The barriers which preclude
pharmacists from being fully
effective in delivering
pharmaceutical care services to
psychiatric patients include
a. centralised system of the
‘free’ distribution of several
classes of psychotropic
medicines to a majority of
patients which bypasses the
community pharmacists
 b. legislative structures
controlling supply of drugs of
dependence which restrict
pharmacists’ intervention.
c. pharmacy logistics, such as
lack of private area, lack of
time, limited computerisation
and lack of teamwork with
other health professionals
d. all of the above
Select only ONE option in each question
by ticking the respective box
on the Response Sheet (page 39).
